

CURRICULUM VITAE

John James Crowley, Ph.D.

Current Address: Cancer Research And Biostatistics
1730 Minor Avenue, Suite 1900
Seattle, WA 98101-1468
www.crab.org
www.swogstat.org

Phone: (206) 839-1720
Email: johnc@crab.org

Education: Pomona College, BA, (Mathematics), 1968
University of Washington, MS,
(Biomathematics), 1970
University of Washington, Ph.D.,
(Biomathematics), 1973

Positions:

NIH Post-doctoral Fellow, Department of Statistics and Division of Biostatistics, Department of Community and Preventive Medicine, Stanford University, 1973-74.
Assistant Professor, Departments of Human Oncology and Statistics, University of Wisconsin-Madison, 1974-79.
Associate Professor, Departments of Human Oncology and Statistics, University of Wisconsin-Madison, 1979-81.
Associate Member, Fred Hutchinson Cancer Research Center, Seattle, Washington, 1981-84.
Associate Professor, Department of Biostatistics, University of Washington, Seattle, Washington, 1981-84.
Program Head, Biostatistics, Fred Hutchinson Cancer Research Center, 1983-1994.
Member, Fred Hutchinson Cancer Research Center, Seattle, Washington, 1984-2001.
Professor, Department of Biostatistics, University of Washington, Seattle, Washington, 1984-2005.
Group Statistician and Director of Statistical Center, Southwest Oncology Group, 1984-present.
President and Chief Executive Officer, Cancer Research And Biostatistics, 1997-present.

Honors:

Spiegelman Award, American Public Health Association, 1985
Fellow, American Statistical Association, 1988
Fellow, American Association for the Advancement of Science, 1991
First Annual Kashinath Patil Lecturer, 1999

Societies:

American Association for Cancer Research
 American Association for the Advancement of Science
 American Society for Clinical Oncology
 American Statistical Association
 International Biometrics Society
 International Association for the Study of Lung Cancer
 Society for Clinical Trials

Professional Activities:**Editorial:**

Associate Editor, Journal of the American Statistical Association, (Theory and Methods), 1979-82.
 Associate Editor, Statistics and Probability Letters, 1982-84.
 Associate Editor, Annals of Statistics, 1983-84.
 Statistical Editor, Journal of Thoracic Oncology, 2006-present.

National:

National Research Council Committee on Department of Energy Research on Health Effects of Ionizing Radiation, 1978-79.
 National Research Council Committee on Federal Research on Biological and Health Effects of Ionizing Radiation, 1979-81.
 Co-organizer, Institute for Mathematical Statistics Special Topics Conference on Survival Analysis, October 1981.
 Regional Committee, Biometric Society, Western North American Region, 1983-85.
 Program Chairman, Biometric Society, Western North American Region, 1984.
 Member, Ad Hoc Panel of Experts associated with the Scientific Reports Review Subcommittee, National Toxicology Program, 1985-86.
 Contributed Papers and Publications Chairman, 13th International Biometrics Conference, 1986.
 President, Biometric Society, Western North American Region, 1987 (President-elect, 1986; Past President, 1988).
 Council, International Biometric Society, 1988-91.
 Member, Cancer Clinical Investigations Review Committee, 1987-90.
 Nominating Committee, American Association for the Advancement of Science, Section U (Statistics), 1990-93; Chair, 1992-93.
 Program Coordinator, Biometric Society, Western North American Region, 1990-93.
 Member, External Advisory Committee, San Antonio Cancer Institute, 1996-99.
 External Advisor, Arkansas Center for Myeloma Research, 1995-2001.
 Member, Breast Cancer Consensus Conference Panel, 2000.
 Member, Data and Safety Monitoring Committee, St. Jude's, 2000-present.
 Member, Medical Advisory Board, NexCura, 2000-present.
 Member, External Advisory Committee, University of California at Davis Cancer Center, 2001-present.

International:

Board of Directors, International Myeloma Foundation, 2005-present.

PUBLICATIONS:

1. Breslow N, Crowley J. Large sample properties of the life table and PL estimates under random censorship. *Annals of Statistics* 2:437-453, 1974.
2. Crowley J. Asymptotic normality of a new nonparametric statistic for use in organ transplantation studies. *JASA* 69:1006-1011, 1974.
3. Crowley J. A note on some recent likelihoods leading to the log rank test. *Biometrika* 61:533-538, 1974.
4. Crowley J, Breslow N. Remarks on the conservatism of $(0-E)2/E$ in survival data. *Biometrics* 31:957-962, 1975.
5. Alderman EL, Davies RO, Crowley J, et al. Dose response effectiveness of propranolol for the treatment of angina pectora. *Circulation* 51:964-975, 1975.
6. Crowley J, Hu M. Covariance analysis of heart transplant survival data. *JASA* 72:27-36, 1977.
7. Rose DP, Stauber P, Thiel A, Crowley J, et al. Plasma dehydro-epiandrosterone sulfate, androstenedione and cortisol, and urinary free cortisol excretion in breast cancer. *Eur J Cancer* 3:43-47, 1977.
8. Gould MN, Jirtle R, Crowley J, Clifton K. Re-evaluation of the number of cells involved in the neutron induction of mammary neuroplasms. *Cancer Res* 38:189-192, 1978.
9. Gould MN, Clifton KH, Crowley J. Effects of endocrinological conditions associated with acute versus chronic lactation on the incidence of mammary carcinomas in irradiated rats: Brief communication. *J Natl Cancer Inst* 60:469-471, 1978.
10. Clifton KH, Crowley J. Effects of radiation type & dose & role of glucocorticoids in mammary tumor induction in MtT-grafted rats. *Cancer Res* 38:1507-1513, 1978.
11. Baumgartener LE, Crowley J, Entine S, et al. Influence of sire on BLV infection in progeny. *Zbl. Vet Med B* 25:202-210, 1978.
12. Hoogerland DL, Buchler DA, Crowley J, et al. Estrogen use-- risk of endometrical carcinoma. *Gyn Oncol* 6:451-458, 1978.
13. Dubner HN, Crowley J, Schilling RF. Prognostic value of nucleoli and cell size in chronic lymphocytic leukemia. *Am J Hematol* 4:337-341, 1978.
14. Schilling RF, Crowley J. Prognostic factors in chronic myelocytic leukemia. *Am J Hematol* 7:1-10, 1979.
15. Crowley J. Some extensions of the log rank test. In *Lecture Notes in Medical Informatics 4. Clinical Trials in "Early" Breast Cancer--Methodologic & Clinical Aspects of Treatment Comparisons*. Proceedings, Heidelberg Germany 1978. HR Scheurlen, G Weckesser, I Armbruster, eds. New York: Springer-Verlag, pp. 213-223, 1979.
16. Hunter WG, Crowley J. Hazardous substances, the environment & public health: A statistical viewpoint. *Environ Hlth Perspec* 32:241-254, 1979. Translated into German into two papers: *Arbeitsmedizin, Sozialmedizin, Preventivmedizin* 17:142-146 and 177-181, 1982.
17. Coates AS, Klopp RG, Zarling JM, Borden EC, Crowley J, Carbone PP. Immunologic function during adjuvant BCG immunotherapy for malignant melanoma: Induction of energy. *Cancer Immunol Immunother* 7:175-179, 1979.
18. Pandya KJ, Tormey DC, Davis TE, Falkson G, Banerjee TK, Crowley J. A phase II trial of 6-thioguanine in metastatic breast cancer. *Cancer Treat Rep* 64:191-192, 1980.
19. Pandya KJ, Whitehead R, Crowley J, et al. Elevated plasma aldosterone levels in patients with liver metastases. A rationale for spirono-lactone therapy. *JAMA* 244:171-172, 1980.
20. Hogan TE, Borden EC, Freiburg BL, Vieau J, Hsieh F-Y, Crowley J. Enhancement in recall antigen responses by frequent, repetitive skin testing with candida, mumps, and streptokinase-streptodornase in 38 normal adults. *Cancer Immunol Immunother* 10:27-31, 1980.
21. Hogan TE, Borden EC, Loenhardt PH, Voelkel JG, Crowley J. Growth modification in human cells by Poly I: Poly C Amphotericin B Methyl Ester. In *Interferon: Properties & Clinical Uses*. A Kahn, NO Hill, GL Dorn; eds. Dallas: Leland Fikes Foundation Press, pp. 609-618, 1980.
22. Davis TE, Kahn L, Tormey DC, Larson FC, Anderson SA, Crowley J, Carey RN. Clinical studies of a fast homoarginine-sensitive alkaline phosphate (FHAP) in patients with cancer. *Cancer Res* 41:1110-1113, 1981.
23. Tunca JC, Buchler DA, Mack EA, Ruzicka FF, Crowley J, Carr WF. The management of ovarian cancer caused bowel obstruction. *Gynecol Oncol* 12:186-192, 1981.

24. Chang Y-C, Falkson G, Tormey DC, Crowley J. Phase I-II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine & prednisone in advanced breast cancer. *Cancer Clin Trials* 4:77-79, 1981.
25. Robins HI, Tormey DC, Skelley MJ, Falkson G, Crowley J, Ramirez G, Falkson H. Vindesine: A phase II trial in advanced breast cancer patients. *Cancer Clin Trials* 4(4):371-375, 1981.
26. Breslow N, Crowley J. Contribution to the discussion of the paper "Survival times: Aspects of partial likelihood" by David Oakes. *Intl Stat Review* 49:255-257, 1981.
27. Jirtle RL, Michalopoulos G, McLain JR, Crowley J. Transplantation system for determining the clonogenic survival of parenchymal hepatocytes exposed to ionizing radiation. *Cancer Res* 41:3512-3518, 1981.
28. Tormey DC, Davis TE, Falkson G, Crowley J. Combination chemotherapy + tamoxifen in advanced breast cancer. *Reviews on Endocrine-Related Cancer Supplement* 9, pp. 484-489, 1981.
29. Wiley AL, Wirtanen GW, Davis TE, Ramirez G, Davis HL, Carbone PP, Wolberg WH, Johnson RO, Crowley J. Preliminary results on the treatment of unresectable pancreatic carcinoma with a combination of precision (intra arterial) chemotherapy & precision radiation therapy. In *Pancreatic Cancer: New Directions in Therapy Management*. I Cohn, ed. New York: Masson Pub Co, pp. 97-106, 1981.
30. Brookmeyer R, Crowley J. A confidence interval for the median survival time. *Biometrics* 38:29-41, 1982.
31. Tormey DC, Falkson G, Crowley J, et al. Dibromodulcitol & adriamycin + tamoxifen in advanced breast cancer. *Am Journal of Clinical Oncology Cancer: Clinical Trials* 5:33-39, 1982.
32. Schilling RF, McKnight B, Crowley J. Prognostic value of serum lactic dehydrogenase level in Hodgkin's disease. *J Laboratory Clin Med* 99:382-387, 1982.
33. Brookmeyer R, Crowley J. A k-sample median test for censored survival data. *JASA* 77:433-440, 1982.
34. Crowley J, Voelkel J. Contribution to the discussion of "linear nonparametric tests for comparison of counting processes," by Anderson, Borgan, Gill and Kelding. *Intl Stat Review* 50:247-248, 1982.
35. Chang YC, Falkson G, Tormey DC, Crowley J. A pilot study of mitomycin C & tamoxifen (MT) versus dibromodulcitol adriamycin, & tamoxifen (DAT). *Am Journal of Clinical Oncology* 5:521-525, 1982.
36. Borden EC, Davis TE, Crowley J, et al. Interim analysis of a trial of Levamisole & 5-Fluorouracil in metastatic colorectal carcinoma. In *Immunotherapy of Human Cancer*. W Terry, SA Rosenberg; eds. New York: Elsevier North Holland Inc, pp. 231-235, 1982.
37. Crowley J, Liu PY, Voelkel JG. Estimation of the ratio of hazard functions. *Survival Analysis: IMS Lecture Notes, Monograph Series, Volume 2*. J Crowley, RA Johnson; eds. Hayward CA: The Institute of Mathematical Statistics, pp. 56-73, 1982.
38. Leurgans S, Tsai W-Y, Crowley J. Freund's bivariate exponential distribution & censoring. In *Survival Analysis IMS Lecture Notes Monograph Series, Vol 2*. J Crowley, RA Johnson; eds. Hayward CA: The Institute of Mathematical Statistics, pp. 230-242, 1982.
39. Meeker TC, Siegel MS, Shiota FM, Crowley J, McGuffin RW. Toxicity of amphotericin B, miconazole & ketoconazole to human granulocyte progenitor cells *in vitro*. *Antimicrob Agents Chemother* 23(1):169-171, 1983.
40. Kennedy MS, Deeg HJ, Siegel M, Crowley J, Storb R, Thomas ED. Acute renal toxicity by combined use of amphotericin B & cyclosporin A after allogenic marrow transplantation. *Transplantation* 35(3):211-215, 1983.
41. Hsieh F-Y, Crowley J, Tormey DC. Some test statistics for use in multistate survival analysis. *Biometrika* 70:111-119, 1983.
42. Wade JC, DeJongh CA, Newman KA, Crowley J, et al. Selective antimicrobial modulation as prophylaxis against infection during granulocytopenia: trimethoprim-sulfamethoxazole vs. nalidixic acid. *J Infect Dis* 147:624-634, 1983.
43. Crowley J, Storer BE. Comment on "A reanalysis of the Stanford heart transplant data" by M Aitkin, N Laird, B Francis. *JASA* 78:277-281, 1983.
44. Crowley J: Book review of "Survival Analysis" by Rupert Miller. *American Scientist*, 1983.
45. Voelkel JG, Crowley J. Nonparametric inference for a class of semi-Markov processes with censored observations. *Annals of Statistics* 12:142-160, 1984.
46. Schilling RF, McKnight B, Crowley J. Prognostic value of blood glucose in Hodgkin's disease. *Journal of Clinical Oncology* 2:828-830, 1984.

47. Wade JU, Day LM, Crowley J, et al. Recurrent herpes simplex virus infection after marrow transplant: Role of the specific immune response & acyclovir treatment. *J Infect Dis* 149:750-756, 1984.
48. McKnight B, Crowley J. Tests for differences in tumor incidence based on animal carcinogenesis experiments. *JASA* 79:639-648, 1984.
49. Appelbaum FR, Dahlberg S, Thomas ES, Buckner CD, Cheever MA, Clift RA, Crowley J, et al. Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. *Ann Intern Med* 101:581-588, 1984.
50. Crowley J, Breslow N. Statistical analyses of survival data. In *Annual Review of Public Health, Vol 5*. N Breslow, ed. Palo Alto CA: Annual Reviews Inc, pp. 385-441, 1984.
51. Storer BE, Crowley J. Diagnostics for Cox regression. *Proceedings of the 12th International Biometrics Conference*, pp. 163-175, 1984.
52. Storer BE, Crowley J. A diagnostic for Cox regression and general conditional likelihoods. *JASA* 80:139-147, 1985.
53. Crowley J. Contribution to Panel Discussion, NCI Symposium on Methodology and Quality Assurance in Cancer Clinical Trials, Session 1: Biometric Issues. *Cancer Treat Rep*, 69:1079-1080, 1985.
54. Green SJ, Crowley J. On robust estimation with arbitrarily right-censored data. *Statistics and Probability Letters* 4:303-308, 1986.
55. Weiss GR, Crowley J, Von Hoff DD, et al. Phase II study of fludarabine phosphate for the treatment of advanced non-small cell carcinoma of the lung: A Southwest Oncology Group study. *Cancer Treat Rep* 70:1123-1124, 1986.
56. Livingston RB, Schulman S, Mira JG, Harker G, Vogel S, Coltman CA, Jr., Rivkin SE, Budd GT, Grever MR, Crowley J. Combined alkylators and multiple-site irradiation for extensive small cell lung cancer: A Southwest Oncology Group study. *Cancer Treat Rep* 70:1395-1401, 1986.
57. Tsai WY, Leurgans S, Crowley J. Nonparametric estimation of a bivariate survival function in the presence of censoring. *Annals of Statistics* 14(4):1351-1365, 1986.
58. Goodwin JW, Crowley J, Tranum B, et al. Phase II trial of spiro-germanium in central nervous system tumors: A Southwest Oncology Group study. *Cancer Treat Rep* 71(1):99-100, 1987.
59. Goodman GE, Yen YP, Cox TC, Crowley J. The effect of verapamil on in vitro cytotoxicity of adriamycin and vinblastine in human tumor cells. *Cancer Research* 47:2295-2304, 1987.
60. Kies MS, Mira JG, Crowley J. Multimodal therapy for limited small-cell lung cancer: A randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: A Southwest Oncology Group study. *Journal of Clinical Oncology* 5(4):592-600, 1987.
61. Shields AF, Coonrod DV, Quackenbush RC, Crowley J. Cellular sources of thymidine nucleotides: Studies for PET. *J Nuclear Med* 28:1435-1440, 1987.
62. Lenhard Jr. RE, Enterline JP, Crowley J, Ho GYF. The effects of distance from primary treatment centers on survival among patients with multiple myeloma. *Journal of Clinical Oncology* 5(10):1640-1645, 1987.
63. Stuckey WJ, Crowley JJ, Baker LH, et al. Phase II trial of diaziquone in patients with refractory and relapsing multiple myeloma: A Southwest Oncology Group study. *Cancer Treat Rep* 71(11):1095-1096, 1987.
64. Radosevich CA, Kies MS, Bannon DJ, Mira JG, Crowley J, Livingston RB. Long-term follow-up after induction chemotherapy with or without chest radiation in limited small cell lung cancer (for the Southwest Oncology Group). *Proceedings of the 1987 Adjuvant Therapy Conference*.
65. Early Breast Cancer Trialists' Collaborative Group (Member, Working Party). Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. *New Engl J Med* 319(26):1681-1692, 1988.
66. Rainey JM, Hill JB, Crowley J. Evaluation of fludarabine phosphate in small cell carcinoma: A Southwest Oncology Group study. *Invest New Drugs* 6:45-46, 1988.
67. Sause WT, Crowley J, Eyre HJ, et al. Whole brain irradiation and intrathecal methotrexate in the treatment of solid tumor leptomeningeal metastases. *J Neuro Oncol* 6:107-112, 1988.
68. Jones MP, Crowley J. A general class of nonparametric tests for survival analysis. *Biometrics* 45:157-170, 1989.
69. Moinpour CM, Feigl P, Metch B, Hayden KA, Meyskens FL, Jr, Crowley J. Quality of life endpoints in cancer clinical trials: Review and recommendations. *J Natl Cancer Inst* 81(7):485-495, 1989.

70. Cancer and Leukemia Group B, Children's Cancer Study Group, Eastern Cooperative Oncology Group, Southwest Oncology Group (John J. Crowley). A compendium of statistical terms and procedures used in cancer clinical trials. In *Advances in Oncology*. J Anderson, K Propert, eds. Vol. 5, No. 2, pp.7-30, 1989.
71. Livingston RB, McCracken JD, Crowley J. Southwest Oncology Group trial of simultaneous chemotherapy and radiation therapy in limited small cell lung cancer. In *Small cell lung cancer and non-small cell lung cancer*. RJ Gralla and LH Einhorn. eds., Royal Society of Medicine Services International Congress and Symposium Series No. 150, Royal Society of Medicine Services Limited, pp. 43-49, 1989.
72. Goodman GE, Crowley J, Blasko JC, et al. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: A Southwest Oncology Group study. *Journal of Clinical Oncology* 8(1):39-47, 1990.
73. Tsai WY, Crowley J. A large sample study of generalized maximum likelihood estimators from incomplete data via self-consistency. *Annals of Statistics* 13:1317-1334, 1985. Correction: *Annals of Statistics* 18:470, 1990.
74. Durie BGM, Stock-Novack D, Salmon SE, Finley P, Beckord J, Crowley J, Coltman CA. Prognostic value of pretreatment serum β_2 microglobulin in myeloma: A Southwest Oncology Group study. *Blood* 75(4):823-830, 1990.
75. Karanes C, Crowley J, Sawkar L, et al. Aclacino-mycin A in the treatment of multiple myeloma: A Southwest Oncology Group study. *Invest New Drugs* 8:101-104, 1990.
76. Edelstein MB, Crowley J, Valeriote FA, et al. A phase II study of intravenous 6-thioguanine (NSC-752) in multiple myeloma: A Southwest Oncology Group study. *Invest New Drugs* 8:583-589, 1990.
77. McCracken JD, Janaki LM, Crowley J, et al. Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: A Southwest Oncology Group study. *Journal of Clinical Oncology* 8(5):892-898, 1990.
78. O'Bryan RM, Crowley J, Kim PN, et al. Comparison of etoposide and cisplatin with bis-chloro-ethylnitrosourea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small cell lung cancer. A Southwest Oncology Group study. *Cancer* 65(4):856-860, 1990.
79. Liu PY, Voelkel J, Crowley J. On the ratio of hazard functions in the presence of a nuisance covariate. *Statistics & Probability Letters* 10:135-140, 1990.
80. Jones MP, Crowley J. Asymptotic properties of a general class of nonparametric tests for survival analysis. *Annals of Statistics* 18:1203-1220, 1990.
81. Salmon SE, Tesh D, Crowley J, et al. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: A Southwest Oncology Group study. *Journal of Clinical Oncology* 8(9):1575-1584, 1990.
82. Albain KS, Crowley J, LeBlanc M, Livingston RB. Determinants of improved outcome in small cell lung cancer: An analysis of the 2,580-patient Southwest Oncology Group data base. *Journal of Clinical Oncology* 8(9):1563-1574, 1990.
83. Grever MR, Crowley J, Salmon S, et al. Phase II investigation of pentostatin in multiple myeloma: A Southwest Oncology Group study. *J Natl Cancer Inst* 82(22):1778-1780, 1990.
84. Taylor CW, Crowley J, Williamson SK, et al. Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: A Southwest Oncology Group pilot study. *Journal of Clinical Oncology* 8(11):1811-1817, 1990.
85. Sause WT, Crowley J, Morantz R, et al. Solitary brain metastases: Results of an RTOG/SWOG protocol evaluating surgery +RT versus RT alone. *Am Journal of Clinical Oncology* 13(5):427-432, 1990.
86. Kraut EH, Crowley J, Grever MR, et al. A phase II study of fludarabine phosphate in multiple myeloma: A Southwest Oncology Group study. *Invest New Drugs* 8:199-200, 1990.
87. Gentleman R, Crowley J. Smoothing censored data. *Proceedings of the XVth International Biometric Conference* pp.111-121, 1990.
88. Early Breast Cancer Trialists' Collaborative Group (Member, Working Party). *Treatment of Early Breast Cancer Volume I, Worldwide Evidence 1985-1990*. Oxford University Press, 1990.
89. Vance RB, Crowley J, Macdonald JS, Ahmann FR. Phase II evaluation of menogaril (NSC-269148) in non-small cell lung carcinoma: A Southwest Oncology Group study. *Invest New Drugs* 9:73-75, 1991.
90. Goodman GE, Crowley J, Livingston RB, et al. Treatment of limited small-cell lung cancer with concurrent etoposide/cisplatin and radiotherapy followed by intensification with high dose cyclophosphamide: A Southwest Oncology Group study. *Journal of Clinical Oncology* 9:453-457, 1991.

91. Anderson JR, Crowley J, Propert KJ. Interpretation of survival data in clinical trials. *Oncology* 5(2):104-110, 1991.
92. Taylor SA, Crowley J, Vogel FS, et al. Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors. A Southwest Oncology Group trial. *Invest New Drugs* 9:195-197, 1991.
93. Higano CS, Crowley J, Livingston RB, et al. A weekly cisplatin-based induction regimen for extensive non-small cell lung cancer. *Cancer* 67(10):2439-2442, 1991.
94. Albain KS, Crowley J, Livingston RB. Long-term survival and toxicity in small cell lung cancer, expanded Southwest Oncology Group experience. *Chest* 99:1425-1432, 1991.
95. Ellis GK, Crowley J, Livingston RB, et al. Cisplating and novobiocin in the treatment of non-small cell lung cancer. *Cancer* 67(12):2969-2973, 1991.
96. Grunberg SM, Crowley J, Livingston RB, et al. Treatment of non-small-cell lung cancer with vinblastine and very high-dose cisplatin. A Southwest Oncology Group study. *Cancer Chemother Pharmacol* 28:211-213, 1991.
97. Gentleman R, Crowley J. Graphical methods for censored data. *JASA* 86(515):678-682, 1991.
98. Albain KS, Crowley J, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. *Journal of Clinical Oncology* 9(9):1618-1626, 1991.
99. Weick JK, Crowley J, Natale RB, et al. A randomized trial of five cisplatin-containing treatments in patient with metastatic non-small-cell lung cancer: A Southwest Oncology Group study. *Journal of Clinical Oncology* 9(7):1157-1162, 1991.
100. Taylor SA, Crowley J, Pollock TW, et al. Objective anti-tumor activity of Acivin (AT-125) in patients with recurrent CNS malignancies; A Southwest Oncology Group trial. *Journal of Clinical Oncology* 9(8):1476-1479, 1991.
101. Gentleman R, Crowley J. Local full likelihood estimation for the proportional hazards model. *Biometrics* 47:1283-1296, 1991.
102. Durie BGM, Crowley J, Coltman CA, et al. Phase II evaluation of bisantrene in refractory multiple myeloma, A Southwest Oncology Group study. *Invest New Drugs* 9:329-331, 1991.
103. Saeed SM, Stock-Novack D, Pohlod R, Crowley J, Salmon SE. Prognostic correlation of plasma cell acid phosphatase and beta-glucuronidase in multiple myeloma: A Southwest Oncology Group study. *Blood* 78(12):3281-3287, 1991.
104. Hanson KH, Crowley J, Salmon SE, et al. Evaluation of amonafide in refractory and relapsing multiple myeloma: A Southwest Oncology Group study. *Anti-Cancer Drugs* 2:247-250, 1991.
105. Salmon SE, Beckord J, Pugh RP, Barlogie B, Crowley J. Alpha-Interferon for remission maintenance: Preliminary report on the Southwest Oncology Group study. *Seminars in Oncology* 18(5):33-36 Suppl 7, 1991.
106. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy; 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. *The Lancet* 339(8784):1-15; 71-85, 1992.
107. Mortimer JE, Crowley J, Eyre H, et al. A phase II randomized study comparing sequential and combined intraarterial cisplatin and radiation therapy in primary brain tumors. *Cancer* 69(5):120-123, 1992.
108. LeBlanc M, Crowley J. Relative risk trees for censored survival data. *Biometrics* 48:411-425, 1992.
109. Goodman PJ, Crowley J, Benson C. Creation of a semiannual report for a multicentre co-operative clinical trials group. *Statis Med* 11:1367-1376, 1992.
110. Williamson S, Crowley J, Livingston R, et al. Phase II trial of piroxantrone in advance non-small cell carcinoma of the lung. *Invest New Drugs* 10:29-30, 1992.
111. Jones MP, Crowley J. Nonparametric tests of the markov model for survival data. *Biometrika* 79(3):513-522, 1992.
112. Gentleman R, Crowley J. A graphical approach to the analysis of censored data. *Breast Cancer Res Treat* 22:229-240, 1992.
113. Chou DK, Guy AW, Kunz LL, Johnson RB, Crowley JJ, Krupp JH. Long-term, low-level microwave irradiation of rats. *Bioelectromagnetics* 13:469-496, 1992.
114. Crowley J, Green S. Comment on "Evaluating Therapeutic Interventions" by Thomas R. Fleming. *Statistical Science* 4:441-443, 1992.

115. Jagannath S, Vesole DH, Glenn L, Crowley J, Barlogie B. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. *Blood* 80(7):1666-1672, 1992.
116. Liu PY, Green S, Wolf M, Crowley J. Testing against ordered alternatives for censored survival data. *JASA* 88(421):153-160, 1993.
117. Goodwin JW, Crowley J, Eyre HJ, et al. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: A Southwest Oncology Group study. *J Neurooncol* 15:75-77, 1993.
118. Rusch VW, Albain KS, Crowley JJ, et al. Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. *J Thorac Cardiovasc Surg* 105(1):97-106, 1993.
119. Green S, Crowley J. Data monitoring committees for Southwest Oncology Group clinical trials. *Stat Med* 12:451-455, 1993.
120. Taylor SA, Crowley J, Townsend J, et al. Phase II evaluation of echinomycin (NSC-526417) in patients with central nervous system malignancies. A Southwest Oncology Group study. *J Neurooncol* 15:181-184, 1993.
121. Gandara DR, Crowley J, Livingston RB, et al. Evaluation of cisplatin in metastatic non-small-cell lung cancer: A phase III study of the Southwest Oncology Group. *Journal of Clinical Oncology* 11(5):873-878, 1993.
122. LeBlanc M, Crowley J. Survival trees by goodness of split. *JASA* 88:457-467, 1993.
123. Williamson SK, Crowley J, Livingston RB, Weiss G: Phase II trial of 6-thioguanine administered as 120 hour continuous infusion for refractory or recurrent small cell lung cancer. A Southwest Oncology Group study. *Invest New Drugs* 11:81-83, 1993.
124. Chapman R, Crowley J, Lucas JG, et al. Mitogauzone, cisplatin, and vinblastine in advance non-small cell lung cancer. A Southwest Oncology Group study. *Invest New Drugs* 11:91-92, 1993.
125. Livingston RB, Crowley J, Thompson T, et al. Prolonged, alternating chemotherapy for extensive small cell lung cancer. A Southwest Oncology Group study. *Cancer* 71(11):3509-3513, 1993.
126. Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. *Journal of Clinical Oncology* 11(7):1276-1285, 1993.
127. Eyre HJ, Crowley J, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: A Southwest Oncology Group study. *J Neurosurg* 78:909-914, 1993.
128. Liu PY, Dahlberg S, Crowley J. Selection designs for pilot studies based on survival. *Biometrics* 49:391-398, 1993.
129. Grunberg SM, Crowley J, Livingston R, et al. Extended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. *Journal of Clinical Oncology* 11(8):1598-1601, 1993.
130. Benedetti J, Green S, Lee ML, Crowley J. Report of the ad hoc committee on design of an experiment on double-blind refereeing. *Statistical Science* 8(3):318-330, 1993.
131. Liu PY, Voelkel JO, Crowley J, Wolf M. Sufficient conditions for treatment responders to have longer survival than non-responders. *Stat & Prob Letters* 18:205-208, 1993.
132. Albain KS, Crowley JJ, Hutchins L, et al. Predictors of survival following relapse or progression of small cell lung cancer: Southwest Oncology Group study #8605 and an analysis of the recurrent disease data base. *Cancer* 72(4):1184-1191, 1993.
133. Coiffier B, Philip T, Burnett AK, Symann ML and Panel. Consensus conference on intensive chemotherapy plus hematopoietic stem cell transplantation in malignancies, Lyon, June 4-6, 1993. *Ann Oncol* 5:19-23, 1994.
134. Barlogie B, Anderson K, Berensen J, Crowley J, Cunningham D, Gertz M, Henon P, Horowitz M, Jagannath S, Powles R, Reece D, Reiffers J, Salmon S, Tricot G, Vesole D. Transplants for multiple myeloma. *J Cell Biochem, Suppl* 18B:56, 1994.
135. Barlogie B, Crowley J, Salmon SE, et al. Phase II study of carboplatin (CBDCA) in refractory multiple myeloma: A Southwest Oncology Group study. *Invest New Drugs* 12:53-55, 1994.
136. Crowley J, Green S, Liu PY, Wolf M. Data monitoring committees and early stopping guidelines: The Southwest Oncology Group experience. *Stat Med* 13:1391-1399, 1994.

137. Harrington D, Crowley J, George SL, et al. The case against independent monitoring committees. *Stat Med* 13:1411-1414, 1994.
138. Rusch VW, Albain KS, Crowley J, et al. Neoadjuvant therapy : A novel and effective treatment for stage IIIb non-small cell lung cancer. *Ann Thorac Surg* 58:290-295, 1994.
139. Hazuka MB, Crowley J, Bunn PA, et al. Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: Results of a phase II Southwest Oncology Group study. *Journal of Clinical Oncology* 12(9):1814-1820, 1994.
140. Jagannath S, Vesole DH, Tricot G, Crowley J, Salmon SE, Barlogie B. Hemopoietic stem cell transplants for multiple myeloma. *Oncology* 8(11):89-103, 1994.
141. Salmon SE, Crowley JJ, Grogan TM, et al. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: A Southwest Oncology Group study. *Journal of Clinical Oncology* 12(11):2405-2414, 1994.
142. Vesole D, Barlogie B, Jagannath S, Cheson B, Tricot G, Crowley J. High dose therapy for refractory multiple myeloma: Improved prognosis with better supportive care and double transplants. *Blood* 84(3):950-956, 1994.
143. Crowley J. Perioperative portal vein chemotherapy. In *ASCO Educational Book from 30th Annual Meeting, Dallas TX, May 14-17, pp. 171-175, 1994.*
144. Crowley J, Liu PY: Book review of "Statistical Models Based on Counting Processes" by PK Anderson, O Borgan, RD Gill, and N Keiding. *JASA*, p. 356, 1994.
145. LeBlanc M, Crowley J. Semiparametric regression functionals. *JASA* 90(429):95-105, 1995.
146. Dalton WS, Crowley J, Salmon SS, et al. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma: A Southwest Oncology Group study. *Cancer* 75(3):815-820, 1995.
147. Feigl P, Blumenstein B, Thompson I, Crowley J, Wolf M, Kramer BS, Coltman CA, Brawley OW, Ford LG. Design of the Prostate Cancer Prevention Trial (PCPT). *Control Clin Trials* 16:150-163, 1995.
148. Piantadosi S, Crowley J. An implicitly defined parametric model for censored survival data and covariates. *Biometrics* 51:249-258, 1995.
149. Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L, Cheson B, Crowley J, Barlogie B. Peripheral blood stem cell transplantation for multiple myeloma-identification of favorable variables for rapid engraftment in 225 patients. *Blood* 85(2):588-596, 1995.
150. LeBlanc M, Crowley J. Step-function covariate effects in the proportional-hazards model. *The Canadian Journal of Statistics* 23(2):109-129, 1995.
151. Williamson SK, Crowley JJ, Livingston RB, et al. Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung: A Southwest Oncology Group study. *Invest New Drugs* 13:67-71, 1995.
152. Bunn PA, Crowley J, Kelly K, et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: A prospective phase III randomized study of the Southwest Oncology Group. *Journal of Clinical Oncology* 13(7):1632-1641, 1995.
153. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. *British Medical Journal* 311:899-909, 1995.
154. Early Breast Cancer Trialist's Collaborative Group. Effects of radiotherapy and surgery in early breast cancer: An overview of the randomized trials. *N Engl J Med* 333(22):1444-1455, 1995.
155. Kelly K, Crowley J, Bunn PA, et al. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: A Southwest Oncology Group study. *Journal of Clinical Oncology* 13(12): 2924-2930, 1995.
156. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: Mature results of Southwest Oncology Group Phase II study 8805. *Journal of Clinical Oncology* 13(8):1880-1892, 1995.
157. Tricot G, Jagannath S, Vesole DH, Crowley J, Barlogie B. Relapse of multiple myeloma after autologous transplantation: Survival after salvage therapy. *Bone Marrow Transplant* 16:7-11, 1995.

158. Barlogie B, Anderson K, Berenson J, Crowley J, Cunningham D, Gertz M, Henon P, Horowitz M, Jagannath S, Powles R, Reece D, Reiffers J, Salmon S, Tricot G, and Vesole D. Transplants for Multiple Myeloma. In: K. Dickie and A. Keating (eds.): Autologous Marrow and Blood Transplantation. Proceedings of the Seventh International Symposium, Arlington, Texas, pp. 399-410, 1995.
159. Crowley J, Leblanc M, Gentleman R, Salmon S. Exploratory methods in survival analysis. In: IMS Lect Notes 27:55-77, 1995.
160. LeBlanc M, Crowley JJ. A review of tree-based prognostic models. In: Recent Advances in Clinical Trial Design and Analysis. Peter F. Thall (ed), Kluwer Academic Publishers, pp. 113-124, 1995.
161. Modiano M, Villar-Werstler P, Crowley J, Salmon S. Evaluation of race as a prognostic factor in multiple myeloma: An ancillary of Southwest Oncology Group study 8229. *Journal of Clinical Oncology* 14(3):974-977, 1996.
162. Figlin RA, Crowley JJ, Jacobs EL, et al. Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma: A phase II study of the Southwest Oncology Group. *Cancer* 78:998-1003, 1996.
163. Vesole DH, Tricot G, Jagannath S, Desikan KR, Siegel D, Bracy D, Miller L, Cheson B, Crowley J, Barlogie B. Autotransplants in multiple myeloma: What have we learned? *Blood* 88(3):838-847, 1996.
164. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: Overview of the randomised trials. *The Lancet* 348(9036):1189-1196, 1996.
165. Vesole DH, Jagannath S, Tricot G, Crowley J, Barlogie B. Autologous bone marrow and peripheral blood stem cell transplantation in multiple myeloma. *Cancer Invest* 14(4):378-391, 1996.
166. Crowley J: Book review of "Analysing Survival Data from Clinical Trials and Observational Studies" by Ettore Marubini and Maria Grazia Valsecchi. *Control Clin Trials* 17:353-55, 1996.
167. Liver Infusion Meta-analysis Group. Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. *Journal of the Cancer Institute* 89(7):497-505, 1997.
168. Jagannath S, Vesole DH, Zhang M, Desikan KR, Copeland N, Jagannath M, Bracy D, Jones R, Crowley J, Tricot G, Barlogie B. Feasibility and cost effectiveness of outpatient autotransplants in multiple myeloma. *Bone Marrow Transplant* 20:445-450, 1997.
169. Grozea PN, Crowley JJ, Canfield VA, et al. Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma. A phase II study of the Southwest Oncology Group. *Cancer* 80(6):1029-1033, 1997.
170. Higano CS, Crowley JJ, Veith RV, Livingston RB. A phase II trial of intravenous vinorelbine in previously untreated patients with extensive small cell lung cancer. A Southwest Oncology Group study. *Invest New Drugs* 15:153-156, 1997.
171. Thompson IM, Coltman CA, Crowley J. Chemoprevention of prostate cancer: The Prostate Cancer Prevention Trial. *The Prostate* 33:217-221, 1997.
172. Barlogie B, Jagannath S, Vesole D, Naucke S, Cheson B, Matrox S, Bracy D, Salmon S, Jacobson J, Crowley J, Tricot G. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. *Blood* 89(9):789-793, 1997.
173. Gandara DR, Edelman MJ, Crowley JJ, et al. Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: A Southwest Oncology Group study. *Cancer Chemother Pharmacol* 41:75-78, 1997.
174. Crowley J, LeBlanc M, Jacobson J, Salmon S. Some exploratory tools for survival analysis. In: Lecture Notes In Statistics. Proceedings of the first Seattle symposium in biostatistics: survival analysis, Seattle, Washington, pp. 199-229, 1997.
175. Weick J, Crowley J, Natale R, et al. A randomized trial of five cisplatin-containing treatment in patients with metastatic non-small-cell lung cancer: A Southwest Oncology Group Study. *Classic Papers and Current Comments* 2(1):172-177, 1997.

176. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA(N2) and IIIB non-small-cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805. *Classic Papers and Current Comments* 2(1):145-158, 1997.
177. Gandara DR, Crowley J, Livingston RB, Perez EA, Taylor CW, Weiss G, Neeffe JR, Hutchins LF, Roach RW, Grunberg SM, Braun TJ, Natale RB, Balcerzak SP. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: A phase III study of the Southwest Oncology Group. *Classic Papers and Current Comments* 2(1):178-184, 1997.
178. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer. The Southwest Oncology Group experience. *Classic Papers and Current Comments* 2(1):135-144, 1997.
179. Salmon SE, Crowley JJ, Balcerzak SP, et al. Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: A Southwest Oncology Group study. *Journal of Clinical Oncology* 16(3):890-896, 1998.
180. Thomas CR, Giroux DJ, Stelzer KJ, Craig JB, Laufman LR, Taylor SA, Goodwin JW, Crowley JJ, Livingston RB. Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: A phase II study of the Southwest Oncology Group (SWOG-9229). *Int J Radiat Oncol Biol Phys* 40(5):1039-1047, 1998.
181. Antman K, Crowley JJ, Balcerzak SP, et al. A Southwest Oncology Group and cancer and leukemia group b phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, ewing's sarcoma and rhabdomyosarcoma. *American Cancer Society* 82(7):1288-1295, 1998.
182. Kraut EH, Crowley JJ, Wade JL, et al. Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study. *Journal of Clinical Oncology* 16(2):589-592, 1998.
183. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. *The Lancet* 351(9114):1451-1467, 1998.
184. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. *Journal of Clinical Oncology* 16(7):2459-2465, 1998.
185. Lau DH, Crowley JJ, Gandara DR, et al. Southwest Oncology Group Phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III Non-small-cell lung cancer. *Journal of Clinical Oncology* 16(9):3078-3081, 1998.
186. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. *The Lancet* 352(9132):930-942, 1998.
187. Tsai WY and Crowley J. A note on nonparametric estimators of the bivariate survival function under univariate censoring. *Biometrika* 85(3):573-580, 1998.
188. Berenson J, Crowley J, Barlogie B, Salmon S: Alternate day oral prednisone maintenance therapy improves progression-free and overall survival in multiple myeloma (MM) patients. *Blood* 92:1305, 1998.
189. Barlogie B, Jagannath S, Naucke S, Mattox S, Bracy D, Alexanian R, Crowley J, and Tricot G. Long term follow-up after high dose therapy for high risk multiple myeloma. *Bone Marrow Transplant* 21(11):1101-1107, 1998.
190. Mehta J, Tricot G, Jagannath S, Ayers D, Singhal S, Siegel D, Desikan R, Munshi N, Fassas A, Mattox S, Bracy D, Crowley J, Vesole D, Barlogie B. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? *Bone Marrow Transplant* 21(9):887-892, 1998.
191. Miller TP, Crowley JJ, Mira J, Schwartz JG, Hutchins L, Baker L, Natale R, Chase EM, Livingston RB. A randomized trial of chemotherapy and radiotherapy for stage III Non-small cell lung cancer. *Cancer Therapeutics* 1(4):229-36, 1998.

192. Crowley, J. American Society of Clinical Oncology Educational Book. Los Angeles: ASCO Thirty-Fourth Annual Meeting; 1998. Interpreting clinical trials 2: Factorial designs, subset analyses, and intent to treat.
193. Zhang H, Crowley J, Sox HC, Jr, Olshen RA. Tree-structured statistical methods. In: Armitage P; Colton T, editors. Encyclopedia of Biostatistics. Volume 6. Chichester: John Wiley & Sons; 1998. p. 4561-4573.
194. Green SJ, Crowley J, Blumenstein B, Benedetti J. An open letter to the ASCO leadership and membership. Letter to the editor. *Journal of Clinical Oncology* 16:3478, 1998.
195. Barlogie B, Jagannath S, Desikan R, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar M, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J. Total therapy with tandem transplants for newly diagnosed multiple myeloma. *Blood* 93(1):55-65, 1999.
196. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. *Stat Med* 18:695-706, 1999.
197. Hesketh P, Crowley JJ, Burris III H, et al. Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: A Southwest Oncology Group Phase II Trial. *The Cancer Journal From Scientific American* 5(4):237-241, 1999.
198. Vesole D, Crowley JJ, Catchatourian R, et al. High-dose melphalan with autotransplantation for refractory multiple myeloma: Results of a Southwest Oncology Group Phase II Trial. *Journal of Clinical Oncology* 17(7):2173-2179, 1999.
199. Leigh BR, Gandara DR, Crowley JJ, Furuse K, Livingston RB, Fukushima M, Coltman Jr. C. Summary of the proceedings of the United States-Japan lung cancer clinical trials summit: San Francisco, CA, 20-22 November, 1998. *Lung Cancer* 24:181-191, 1999.
200. LeBlanc M, Crowley J. Using the bootstrap for estimation in group sequential design: An application to a clinical trial for nasopharyngeal cancer. *Stat Med* 18:2635-2644, 1999.
201. Livingston R and Crowley J. Commentary on PBT-1 study of high-dose consolidation versus standard therapy in metastatic breast cancer. *Journal of Clinical Oncology* 17(11):22-24, 1999.
202. Singhal S, Mehta J, Desikan R, et al. Antitumor Activity of thalidomide in refractory multiple myeloma. *N Engl J Med* 341(21):1565-1571, 1999.
203. LeBlanc M and Crowley J. Adaptive regression splines in the Cox model. *Biometrics* 55:204-213, 1999.
204. Grunberg SM, Crowley J, Hande KR, Giroux D, Munshi N, Lau DHM, Schroder LE, Zangmeister MH, Balcerzak SP, Hynes HE, Gandara DR. Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide: A Southwest Oncology clinical and pharmacokinetic study. *Cancer Chemother Pharmacol* 44:461-468, 1999.
205. Hutchins L, Unger J, Crowley JJ, Coltman C, Albain K. Underrepresentation of patients 65 years of age or older in cancer- treatment trials. *N Engl J Med* 341(27):2061-2067, 1999.
206. Pisters KMW, Ginsberg RJ, Giroux DJ, Putnam JB, Kris MG, Johnson DH, Roberts JR, Mault J, Cruz A, Crowley JJ, Bunn Jr. P. Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. *The Journal of Thoracic and Cardiovascular Surgery* March:429-439, 2000.
207. Early Breast Cancer Trialist' Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trails. *The Lancet* 355(9217):1757-1770, 2000.
208. Mick R, Crowley JJ, Carroll RJ. Phase II clinical trial design for Noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. *Control Clin Trials* 21(4):343-359, 2000.
209. Liu PY, Anderson G, Crowley J. Observational studies and randomized trials: Letter to the editor. *N Engl J Med* 343(16):1195, 2000.

210. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, Zangari M, Munshi N, Anaissie E, Spoon D, Siegel D, Jagannath S, Vesole D, Epstein J, Shaughnessy J, Fassas A, Lim S, Roberson P, Crowley J. Results of high dose therapy for 1,000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. *Blood* 95:4008-4010, 2000.
211. Rusch VW, Giroux DJ, Kraut MJ, Crowley JJ, Hazuka M, Johnson D, Goldberg M, Detterbeck F, Shepherd F, Burkes R, Winton T, Deschamps C, Livingston R, Gandara D. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). *Journal of Thoracic and Cardiovascular Surgery* 121(3):472-483, 2001.
212. Dhodapkar MV, Jacobson JL, Gertz MA, Rivkin SE, Roodman GD, Tuscano JM, Shurafa M, Kyle RA, Crowley JJ, Barlogie B. Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). *Blood* 98:41-48, 2001.
213. Kelly K, Crowley JJ, Bunn Jr PA, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR. Randomized phase II trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced Non-Small-Cell lung cancer: A Southwest Oncology Group Trial. *Journal of Clinical Oncology* 19(13):3210-3218, 2001.
214. Thomas CR, Giroux DJ, Janaki LM, Turrisi AT, Crowley JJ, Taylor SA, McCracken JD, Shankir Giri PG, Gordon W, Livingston RB, Gandara DR. Ten-year follow-up of Southwest Oncology Group 8269: a phase II trial of concomitant cisplatin-etoposide and daily thoracic radiotherapy in limited small-cell lung cancer. *Lung Cancer* 33(2-3):213-219, 2001.
215. Crowley J, Jacobson J, Alexanian R. Standard-dose therapy for multiple myeloma: the Southwest Oncology Group experience. *Seminars in Hematology* 38(3):203-208, 2001.
216. Hoque A, Albanes D, Lippman SM, Spitz D, Taylor PR, Klein E, Thompson IM, Goodman PJ, Stanford JL, Crowley JJ, Coltman CA, Santella RM. Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *Cancer Causes and Control* 12:627-633, 2001.
217. Faraggi D, LeBlanc M, Crowley J. Understanding neural networks using regression trees: an application to multiple myeloma survival data. *Stat Med* 20:2965-2976, 2001.
218. Kelly K, Lovato L, Bunn Jr. PA, Livingston RB, Zangmeister J, Taylor SA, Roychowdhury D, Crowley J, Gandara DR. Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: A phase II trial of the Southwest Oncology Group. *Clin Cancer Res* 7:2325-2329, 2002.
219. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassas A, Crowley J, Tricot G, Barlogie B and Shaughnessy S. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. *Blood* 99:1745-1757, 2002.
220. Weick JK, Crowley JJ, Hussein MA, Moore DF, Barlogie B. The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II: A Southwest Oncology Group study. *Invest New Drugs* 20:117-121, 2002.
221. Moinpour CM, Lyons B, Grevstad P, Lovato LC, Crowley J, Czaplicki K, Buckner ZM, Ganz PA, Kelly K, Gandara DR. Quality of life in advanced non-small-cell lung cancer: Results of a Southwest Oncology Group randomized trial. *Quality of Life Research* 11:115-126, 2002.

222. Berenson R, Crowley JJ, Grogan TM, Zangari M, Briggs AD, Mills GM, Barlogie B, Salmon SE. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. *Blood* 99(9):3163-3168, 2002.
223. Ramsey SD, Moinpour CM, Lovato LC, Crowley JJ, Grevstad P, Presant CA, Rivkin SE, Kelly K, and Gandara DR. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. *J Natl Cancer Inst* 94(4):291-297, 2002.
224. Albain K, Crowley JJ, Turrisi III AT, Gandara DR, Farrar WB, Clark JI, Beasley KR, Livingston RB. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB Non-small-cell lung cancer: A Southwest Oncology Group Phase II Study, SWOG 9019. *Journal of Clinical Oncology* 20(16):3454-3460, 2002.
225. LeBlanc M, Jacobson J, Crowley J. Partitioning and peeling for constructing prognostic groups. *Stat Methods Med Res* 11:247-274, 2002.
226. Pauler DK, Gower KB, Goodman PJ, Crowley JJ, Thompson IM. Biomarker-based methods for determining noncompliance in a prevention trial. *Control Clin Trials* 23:675-685, 2002.
227. Gandara DR, Chansky K, Albain KS, Leigh BR, Gaspar LE, Lara PN Jr, Burris H, Gumerlock P, Kuebler JP, Bearden JD, Crowley J, Livingston R. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group study S9504. *Journal of Clinical Oncology* 21(10):2004-2010, 2003.
228. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. The influence of finasteride on the development of prostate cancer. *N Engl J Med* 349(3):215-224, 2003.
229. Jacobson JL, Hussein MA, Barlogie B, Durie BGM, Crowley J. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. *British Journal of Haematology* 122:441-450, 2003.
230. Jacobson J, Barlogie B, Shaughnessy J, Drach J, Tricot G, Fassas A, Zangari M, Giroux DJ, Crowley J, Hough A, Sawyer J. MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants. *British Journal of Haematology* 122:430-440, 2003.
231. Dhodapkar MV, Jacobson JL, Gertz MA, Crowley JJ, Barlogie B. Prognostic Factors and Response to Fludarabine Therapy in Waldenstrom's Macroglobulinemia: an update of the US Intergroup trial (SWOG S9003). *Seminars in Oncology* 30(2):220-225, 2003.
232. Unger JM, LeBlanc M, Crowley JJ, Grossman B, Natale RB, Wozniak AJ, Berenson JR, List AF, Peters WA III, Flanigan RC, Macdonald JS, Al-Sarraf M, Thompson IM, and Coltman CA Jr. Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: The Karnofsky memorial lecture. *Journal of Clinical Oncology* (21)23:246-252, 2003.
233. Edelman MJ, Chansky K, Gaspar LE, Leigh B, Weiss GR, Taylor SA, Crowley J, Livingston R, Gandara DR. Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713. *Journal of Clinical Oncology* 22(1): 127- 132, 2004.
234. Tangen C, Goodman P, Crowley J and Thompson I. Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials. *J Urol* 171:S64-S67, 2004.
235. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ and Coltman Jr. CA. Prevalence of prostate cancer among men with prostate-specific antigen level ≤ 4.0 ng per milliliter. *N Engl J Med* 350(22):2239-2246, 2004.
236. Durie BGM, Jacobson J, Barlogie B and Crowley J. Magnitude of response with myeloma frontline therapy does not predict outcome: Importance of time to progression in Southwest Oncology Group Chemotherapy Trials. *Journal of Clinical Oncology* 22(10):1857-1863, 2004.

237. Hardin J, Waddell M, Page CD, Zhan F, Barlogie B, Shaughnessy J and Crowley J. Evaluation of multiple models to distinguish closely related forms of disease using DNA microarray data: an application to multiple myeloma. *Statistical Applications in Genetics and Molecular Biology* 3(1):1-21, 2004.
238. Gandara D, West H, Chansky K, Davies A, Lau D, Crowley J, Gumerlock P, Hirsch F and Franklin W. Bronchioloalveolar carcinoma: A model for investigating the biology of epidermal growth factor receptor inhibition. *Clin Cancer Res* 10(suppl):4205s-4209s, 2004.
239. IASLC. An open letter to all members of the IASLC. *Lung Cancer* 45:119-120, 2004.
240. Edelman, MJ, Clark JL, Chansky K, Albain K, Bhoopalam N, Weiss GR, Giguere JK, Kelly K, Crowley J and Gandara D. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. *Clin Cancer Res* 10:5022-5026, 2004.
241. Goodman PJ, Tangen CM, Crowley JJ, Carlin SM, Ryan A, Coltman CA Jr., Ford LG and Thompson I. Implementation of the Prostate Cancer Prevention Trial (PCPT). *Control Clin Trials* 25:203-222, 2004.
242. Le Q.-T., McCoy J, Williamson S, Le Q-T, Ryu J, Gaspar LE, Edelman MJ, Dakhil SR, Sides SD, Crowley JJ, and Gandara DR. Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study. *Clin Cancer Res* 10:5418-5424, 2004.
243. Dhodapka MV, Hussein MA, Rasmussen E, Solomon A, Larson RA, Crowley JJ, Barlogie B. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. *Blood* 104(12):3520-3526, 2004.
244. Lippman S, Goodman P, Klein E, Parnes H, Thompson IM Jr., Kristal AR, Santella RM, Probstfield JL, Moinpour CM, Albanes D, Taylor PR, Minasian LM, Hoque A, Thomas S, Crowley JJ, Gaziano JM, Stanford JL, Cook ED, Fleshner NE, Leiber MM, Walther PH, Khuri FR, Karp DD, Schwartz GG, Ford LG and Coltman CA Jr. Designing the Selenium and Vitamin E cancer prevention trial (SELECT). *J Natl Cancer Inst* 97(2):94-102, 2005.
245. Unger JM, Thompson IM Jr, LeBlanc M, Crowley JJ, Goodman PJ, Ford LG, Coltman CA, Jr. Estimated impact of the Prostate Cancer Prevention Trial on population mortality. *Cancer* 103(7):1375-1380, 2005.
246. Brown G and Crowley J. Is there any hope for Vitamin E? *JAMA* 293(11):1387-1390, 2005. Gaspar LE, Chansky K, Albain KS, Vallieres E, Rusch V, Crowley JJ, Livingston RB and Gandara DR. Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: A retrospective review by the Southwest Oncology Group. *Journal of Clinical Oncology* 23(13):2955-2961, 2005.
247. Greipp PR, San Miguel J, Durie BGM, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Harousseau JL, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. International Staging System for Multiple Myeloma. *Journal of Clinical Oncology* 23(15):1-9, 2005.
248. Jagannath, S., Durie BGM, Wolf J, Camacho E, Irwin D, Lutzky J, McKinley M, Gabayan E, Mazumder A, Schenkein D, Crowley J. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. *British Journal of Hematology* 129:776-783, 2005.
249. Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, Bunn Jr PA, Franklin WA, Crowley JJ and Gandara DR. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. *Journal of Clinical Oncology* 23(36): 2005.
250. LeBlanc M, J Moon and J Crowley. Adaptive risk group refinement. *Biometrics* 61:370-378, 2005.

251. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, Parnes HL and Coltman CA Jr. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. *JAMA* 294(1), 2005.
252. Williamson S, Crowley JJ, Lara Jr. PN, McCoy J, Lau DHM, Tucker RW, Mills GM and Gandara DR. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. *Journal of Clinical Oncology* 23(36):9097-9104, 2005.
253. Turrisi A, Crowley J, Albain K, Gaspar L and Gandara D. Southwest Oncology Group: two decades of experience in non-small cell lung cancer. *Seminars in Oncology* 32(supp 3):119-121, 2005.
254. Unger J, Coltman CA Jr, Crowley J, Hutchins L, Martino S, Livingston R, Macdonald J, Blanke C, Gandara D, Crawford E and Albain K. Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. *Journal of Clinical Oncology* 24(1):141-144, 2006.
255. Barlogie B, Kyle R, Anderson K, Greipp P, Lazarus H, Hurd D, McCoy J, Dakhil S, Lanier K, Chapman C, Cromer J, Salmon S, Durie B and Crowley J. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US intergroup trial S9321. *Journal of Clinical Oncology* 24(6):929-935, 2006.
256. Hesketh P, Chansky K, Lau DHM, Doroshow JH, Moinpour C, Chapman RA, Goodwin W, Gross HM, Crowley JJ and Gandara DR. Sequential vinorelbine and docetaxel in advanced Non-small-cell lung cancer patients age 70 and older and/or with a performance status of 2: A phase II trial of the Southwest Oncology Group (s0027). *Journal of Thoracic Oncology* 1(6):537-544, 2006.
257. Hesketh P, McCoy J, Dunphy II FR, Bearden III JD, Weiss GR, Giguere JK, Atkins JN, Dakhil SR, Kelly K, Crowley JJ and Gandara DR. Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914. *Journal of Thoracic Oncology* 1(9):991-995, 2006.
258. Lara Jr. P, Chansky K, Davies AM, Franklin WA, Gumerlock PH, Guaglianone PP, Atkins JN, Farneth N, Mack PC, Crowley JJ and Gandara DR. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group Phase II Trial (S0327). *Journal of Thoracic Oncology* 1(9):996-1001, 2006.
259. Goldstraw P and Crowley J. The International Association for the Study of Lung Cancer international staging project on lung cancer. *Journal of Thoracic Oncology* 1(4):281-286, 2006.
260. Goodman P, Thompson IM, Tangen CM, Crowley J, Ford LG and Coltman Jr. CA. The prostate cancer prevention trial: design, biases and interpretation of study results. *Journal of Urology* 175:2234-2242, 2006.
261. Caban-Holt AM, Schmitt FA, Runyons CR, Kryscio RJ, Medidondo MS, Healey MS, Markesbery WR, Coltman Jr. CA, Crowley JJ, Goodman PJ and Hartline JL. Studying the effects of Vitamin E and Selenium for Alzheimer's disease prevention: the Preadvise model. *Research and Practice in Alzheimer's Disease* 11:124-130, 2006.
262. Hanamura I, Stewart J, Huang Y, Zhan F, Santra M, Sawyer J, Hollmig K, Zangarri M, Pineda-Roman M, van Rhee F, Cavallo F, Burington B, Crowley J, Tricot G, Barlogie B and Shaughnessy Jr. J. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myelomas and is related to prognosis and disease progression following tandem stem-cell transplantation. *Blood* 108(5):1724-1732, 2006.
263. Davies AM, Chansky K, Lau DHM, Leigh BR, Gaspar LE, Weiss GR, Wozniak AJ, Crowley J, Gandara DR. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III Non-Small-Cell lung cancer: SWOG S9712. *Journal of Clinical Oncology* 24(33):5242-5246, 2006.

264. Gandara DR, Chansky K, Albain KS, Gaspar LE, Lara Jr. PN, Kelly K, Crowley J, Livingston R. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB Non-Small-Cell lung cancer: a phase II Southwest Oncology Group study (S9504). *Clinical Lung Cancer* 8(2):116-121, 2006.
265. Govindan R, Crowley J, Schwartzberg, L, Kennedy P, Williams C, Ekstrand B, Sandler A, Juanakais D, Bolejack V and Ghalie R. Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies. *Journal of Clinical Oncology* 24(30):4848-4854, 2006.
266. Barlogie B, Zangari M, Bolejack V, Hollmig K, Anaissie E, van Rhee F, Pineda-Roman M, Mohiuddin A, Crowley J and Tricot G. Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma. *Clinical Lymphoma Myeloma* 6(6):469-474, 2006.
267. West HL, Franklin WA, McCoy J, Gumerlock P, Vance R, Lau DHM, Chansky K, Crowley JJ, Gandara DR. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group study S0126. *Journal of Clinical Oncology* 24(12):1807-1813, 2006.
268. Lara PN Jr., Chansky K, Davies AM, Franklin WA, Gumerlock PH, Guaglianone PP, Atkins JN, Farneth N, Mack PC, Crowley JJ, Gandara DR. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). *Journal of Thoracic Oncology* 1(9):996-1001, 2006.
269. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B and Shaughnessy Jr. JD. The molecular classification of multiple myeloma. *Blood* 108(6):2020-2028, 2006.
270. Hoering A, Crowley J. Clinical Trial Designs for Multiple Myeloma. *Clinical Advances in Hematology & Oncology* 5(4):309-318, 2007.
271. Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy Jr. JD, Epstein J, van Hemert R, Erden E, Hoering A, Crowley J, Ferris E, Hollmig K, van Rhee F, Zangari M, Pineda-Roman M, Mohiuddin A, Yaccoby S, Sawyer J and Angtuaco EJ. Magnetic resonance in multiple myeloma: diagnostic and clinical implications. *Journal of Clinical Oncology* 25(9):1121-1128, 2007.
272. Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Winton T, Johnson DH, Shulman L, Shepherd F, Deschamps C, Livingston RB and Gandara D. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of southwest oncology group trial 9416 (intergroup trial 0160). *Journal of Clinical Oncology* 25(3):313-318, 2007.
273. Redman M and Crowley J. Small randomized trials. *Journal of Thoracic Oncology* 2(1):1-2, 2007.
274. Hesketh PJ, Lilenbaum RC, Chansky KC, Dowlatti A, Graham P, Chapman RA, Crowley J and Gandara D. Chemotherapy in patients > 80 with advanced non-small-cell lung cancer: combined results from sWOG 0027 and LUN 6. *Journal of Thoracic Oncology* 2(6): 494-498, 2007.
275. Akerley W, McCoy J, Hesketh PJ, Goodwin W, Bearden JD, Atkins JN, Chansky K, Crowley J and Gandara D. Gemcitabine and Irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119. *Journal of Thoracic Oncology* 2(6): 526-530, 2007.
276. Hesketh P, Chansky K, Isreal V, Grapski R, Mekhail T, Spriidonidis C, Mills G, Kelly K, Crowley J and Gandara D. Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group study 9718. *Journal of Thoracic Oncology* 2(5):440-444, 2007.
277. Rami-Porta R, Ball D, Crowley J, Grioux D, Jett J, Travis W, Tsuboi M, Vallieres E and Goldstraw P. The IASLC Lung Cancer staging project: proposals for the revision of the T descriptors in the forthcoming (Seventh) edition of the TNM Classification for lung cancer. *Journal of Thoracic Oncology* 2(7):593-602, 2007.

278. Rusch V, Crowley J, Giroux D, Goldstraw P, Im J, Tsuboi M, Tshuchiya R and Vansteenkiste J. The IASLC Lung Cancer staging project: proposals for the revision of the N descriptors in the forthcoming (seventh) edition of the TNM Classification for lung cancer. *Journal of Thoracic Oncology* 2(7):603-612, 2007.
279. Sheperd F, Crowley J, Van Houtte P, Postmus P, Carney D, Chansky K, Shaikh Z and Goldstraw P. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. *Journal of Thoracic Oncology* 2(12):1067-1077, 2007.
280. Haessler J, Shaughnessy JJ, Zhan F, Crowley J, Epstein J, van Rhee F, Anaissie E, Pineda-Roman M, Zangari M, Hollmig K, Mohiuddin A, Alsayed Y, Hoering A, Tricot G and Barlogie B. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. *Clinical Cancer Research* 12(23):7073-7079, 2007.
281. Shaughnessy JD Jr., Haessler J, van Rhee F, Anaissie E, Pineda-Roman M, Cottler-Fox M, Hollmig K, Zangari M, Mohiuddin A, Alsayed Y, Graziutti M, Epstein J, Crowley J and Barlogie B. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics. *British Journal of Haematology* 127(6):530-536, 2007.
282. Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, Cottler-Fox M, Mohiuddin A, Alsayed Y, Tricot G, Bolejack V, Zangari M, Epstein J, Petty N, Steward D, Jenkins B, Gurley J, Sullivan E, Crowley J and Shaughnessy JD Jr. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. *British Journal of Haematology* 138(2):176-185, 2007.
283. Barlogie B, Tricot G, Haessler J, van Rhee F, Cottler-Fox M, Anaissie E, Waldron J, Pineda-Roman M, Thertulien R, zangari M, Hollmig K, Mohiuddin A, Alsayed Y, Hoering A, Crowley J and Sawyer J. Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989. *Blood* 111(1):94-100, 2008.
284. Zangari M, van Rhee F, Anaissie E, Pineda-Roman M, Haessler J, Crowley J and Barlogie B. Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1. *British Journal of Haematology* 141(4):433-444, 2008.
285. Lara Jr. P, Redman M, Kelly K, Edelman J, Williamson S, Crowley J and Gandara D. Disease control rate at 8 weeks predicts clinical benefit in advanced Non-Small-cell lung cancer: results from Southwest Oncology Group Randomized Trials. *Journal of Clinical Oncology* 26(3):463-467, 2008.
286. Barlogie B, Anaissie E, van Rhee F, Pineda-Roman M, Zangari M, Shaughnessy JJ, Epstein J and Crowley J. The Arkansas approach to therapy of patients with multiple myeloma. *Best Practice & Research Clinical Haematology* 20(4):761-781, 2008.
287. Blanke C, Rankin C, Demetri G, Ryan C, von Mehren M, Benjamin R, Raymond A, Branwell V, Baker L, Maki R, Tanaka M, Hecht J, Heinrich M, Fletcher C, Crowley J and Borden E. Phase III Randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. *Journal of Clinical Oncology* 26:626-632, 2008.
288. Barlogie B, van Rhee F, Shaughnessy JD Jr., Anaissie E and Crowley J. Making progress in treating multiple myeloma with total therapies: issue of complete remission and more. *Leukemia* 22(8):1633-1636, 2008.
289. Pineda-Roman M, Zangari M, Anaissie E, Tricot G, Van Rhee F, Crowley J, Shaughnessy JD Jr. and Barlogie B. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. *British Journal of Haematology* 140:625-634, 2008.

290. Goldman B, LeBlanc M and Crowley J. Interim futility analysis with intermediate endpoints. *Clinical Trials* 5:14-22, 2008.
291. Mok T and Crowley J. Big question, small answer. *Journal of Thoracic Oncology* 3(2):105-106, 2008.
292. Travis WD, Brambilla E, Rami-Porta R, Vallieres E, Tsuboi M, Rusch V, Goldstraw P, International Staging Committee. Visceral pleural invasion: pathologic criteria and use of elastic stains. Proposal of the 7th edition of the TNM classification for Lung Cancer. *Thoracic Oncology* 3(12):1384-1390, 2008.
293. Pineda-Roman M, Zangari M, van Rhee F, Anaissie E, Szymonifka J, Hoering A, Petty N, Crowley J, Shaughnessy JD Jr., Epstein J and Barlogie B. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. *Leukemia* 24:1-9, 2008.
294. van Rhee F, Shaughnessy JD Jr., Anaissie E, Siegel D, Hoering A, Zeldis J, Jenkins B, Singhal S, Mehta J, Crowley J, Jagannath S and Barlogie B. First thalidomide clinical trial in multiple myeloma: a decade later. *Blood* 112(4):1035-1038, 2008.
295. Barlogie B, Anaissie E, Haessler J, van Rhee F, Pineda-Roman M, Hollmig K, Alsayed Y, Epstein J and Shaughnessy JD Jr. Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. *Cancer*: 2008.
296. Barlogie B, Haessler J, Pineda-Roman M, Anaissie E, van Rhee F, Kiwan E, Steward D, Gurley J, Jenkins B and Crowley J. Completion of pre-maintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designs. *Cancer* 112(12):2720-2725, 2008.
297. Kelly K, Chansky K, Gaspar L, Albain KS, Jett J, Ung YC, Lau DHM, Crowley JJ and Gandara DR. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III Non-Small-Cell lung cancer: SWOG s0023. *Journal of Clinical Oncology* 26(15):2450-2456, 2008.
298. Arzoumanian V, Hoering A, Sawyer J, van Rhee F, Bailey C, Gurley J, Shaughnessy JD Jr., Anaissie E, Crowley J, Barlogie B. Suppression of abnormal karyotype predicts superior survival in multiple myeloma. *Leukemia* 22(4):850-855, 2008.
299. Ludwig H, Durie BGM, Bolejack V, Turesson I, Kyle RA, Blade J, Fonseca R, Dimopoulos M, Shimizu K, San Miguel J, Westin J, Harousseau JL, Beksac M, Boccadoro M, Palumbo A, Barlogie B, Shustik C, Cavo M, Greipp PR, Joshua D, Attal M, Sonneveld P and Crowley J. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. *Blood* 111(8):4039-4047, 2008.
300. Hoering A, LeBlanc M and Crowley J. Randomized phase III clinical trial designs for targeted agents. *Clinical Cancer Research* 14(14):4358-4367, 2008.
301. Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn Jr. PA, Varella-Garcia M, Gandara DR. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in Non-Small-Cell lung cancer patients treated with cetuximab and chemotherapy. *Journal of Clinical Oncology* 26(20):3351-3367, 2008.
302. Barlogie B, van Rhee F, Shaughnessy JD Jr., Epstein J, Yaccoby S, Pineda-Roman M, Hollmig K, Alsayed Y, Hoering A, Szymonifka J, Anaissie E, Petty N, Kumar NS, Srivastava G, Jenkins B, Crowley J, Zeldis JB. Seven year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. *Blood* 112(8):3122-3125, 2008.
303. Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN Jr., Franklin WA, Le QT, Crowley JJ and Gandara DR. Lower osteopontin plasma levels are associated with superior outcomes in advanced Non-Small-Cell lung cancer patients receiving platinum-based chemotherapy: SWOG study S0003. *Journal of Clinical Oncology* 26(29):4771-4776, 2008.

304. van Ness B, Ramos C, Haznadar M, Hoering A, Crowley J, Jacobus S, Oken M, Rajkumar V, Greipp P, Barlogie B, Durie B, Katz M, Atluri G, Fang G, Gupta R, Steinbach M, Kumar V, Mushlin R, Johnson D and Morgan G. Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression free survival. *BMC Med* 8(6):26, 2008.
305. Hesketh PJ, Chansky K, Wozinak AJ, Hirsch FR, Spreafico A, Moon J, Mack PC, Marchello BT, Franklin WA, Crowley JJ, Gandara DR. Southwest Oncology Group phase II trial (s0341) of erlotinib (OSI-774) in patients with advanced Non-Small-Cell lung cancer and a performance status of 2. *Journal of Thoracic Oncology* 3(9):1026-1031, 2008.
306. Burington B, Barlogie B, Zhan F, Crowley J and Shaughnessy JD Jr. Tumor cell expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma. *Clinical Cancer Research* 14(15):4821-4829, 2008.
307. Johnson DC, Corthals S, Ramos C, Hoering A, Cocks K, Dickens NJ, Haessler J, Goldschmidt H, Child JA, Bell SE, Jackson G, Baris D, Rajkumar SV, Davies FE, Durie BG, Crowley J, Sonneveld P, van Ness B, Morgan GJ. Genetic associations with thalidomide venous thrombotic events in myeloma identified using targeted genotyping. *Blood* 112(13):4924-4934, 2008.
308. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian IM, Gaziano JM, Hartline J, Parsons JK, Bearden JD, Crawford ED, Goodman GE, Cluadio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Talyor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL, Baker LH, Coltman Jr. CA. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). *JAMA* 301(1):102-103, 2008.
309. Travis WD, Giroux DJ, Chansky K, Crowley J, Asamura H, Brambilla E, Jett J, Kennedy C, Rami-Porta R, Rusch VW and P G. The IASLC Lung Cancer Staging Project. Proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM classification for lung cancer. *Journal of Thoracic Oncology* 3(11):1213-1223, 2008.
310. Barlogie B, Pineda-Roman M, van Rhee F, Haessler J, Anaissie E, Hollming K, Alsayed Y, Waheed S, Petty N, Epstein J, Shaughnessy JD Jr., Tricot G, Zangari M, Zeldis J, Crowley J. Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. *Blood* 112(8):3115-3121, 2008.
311. Dhodapkar MV, Hoering A, Gertz MA, Rivkin S, Szymonifka J, Crowley J, Barlogie B. Long term survival in Waldenstrom Macroglobulinemia - 10 year follow-up of Southwest Oncology Group (SWOG) directed intergroup trial S9003. *Blood* 113(4):793-796, 2008.
312. Borden EC, Klugger H and Crowley J. Apoptosis: a clinical perspective. *Nature Reviews* 7:959, 2008.
313. Nair B, Waheed S, Szymonifka J, Shaughnessy JD Jr., Crowley J and Barlogie B. Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols. *British Journal of Haematology* 145(1):131-146, 2008.
314. Rubenstein L, Crowley J, Ivy P, LeBlanc M and Sargent DJ. Randomized Phase II Designs. *Clinical Cancer Research* 15(6):1883-1890, 2009.
315. Rami-Porta R, Crowley J and Goldstraw P. The revised TNM staging system for Lung Cancer. *Annals of Thoracic and Cardiovascular Surgery* 15(1):3-9, 2009.
316. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline J, parsons JK, Bearden III JD, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Leiber WM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Porbstfield JL, Jagpal TJ, Crowley JJ, Meyskens Jr FL, Baker LH and Coltman CA Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers. *JAMA* 301(1):39-51, 2009.

317. Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P and IASLC staging committee. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition fo the TNM classification for lung cancer. *Journal of Thoracic Oncology* 4(5):568-577, 2009.
318. Giroux DJ, Rami-Porta R, Chansky K, Crowley J, Groome PA, Postmus PE, Rusch V, Sculier JP, Shepherd FA, Sobin L, Goldstraw P and IASLC staging committee. The IASLC lung cancer staging project: data elements for the prospective project. *Journal of Thoracic Oncology* 4(6):679-688, 2009.
319. Hoering A, Crowley J, Shaughnessy JD Jr., Hollmig K, Alsayed Y, Szymomifka J, Waheed S, Nair B, van Rhee F, Anaissie E and Barlogie B. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in total therapy protocols. *Blood* 114(7):1299-1305, 2009.
320. Lara Jr. PN, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K and Gandara DR. Phase III of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-call lung cancer: clinical and pharmacogenomic results form SWOG 0124. *Journal of Clinical Oncology* 27(15):2350-2355, 2009.
321. Chansky K, Sculier JP, Crowley J, Giroux DJ, Van Meerbeeck J and Goldstraw P. The International Association for the Study of Lung Cancer Staging Project: Prognostic factors and pathologic TNM stage in surgically managed Non-small cell lung cancer. *Journal of Thoracic Oncology* 4(7):792-801, 2009.
322. Le QT, Moon J, Redman MW, Williamson SK, Lara Jr. PN, Goldberg Z, Gaspar LE, Crowley JJ, Moore Jr. DF and Gandara D. Phase II study of tirapazamine, cisplatin and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222. *Journal of Clinical Oncology* 27(18):3014-3019, 2009.
323. LeBlanc M, Rankin C and Crowley J. Multiple histology phase II trials. *Statistics in Clinical Cancer Research* 15(13):4256-4262, 2009.
324. Albain KS, Unger JM, Crowley J, Coltman CA Jr and Hershman DL. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. *Journal of National Cancer Institute* 101(14):984-992, 2009.
325. Hussein MA, Bolejack V, Zonder JA, Durie BGM, Jakubowiak J, Crowley JJ and Barlogie B. Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: A Southwest Oncology Group Trial (S0204). *Journal of Clinical Oncology* 27(21):3510-3517, 2009.
326. Zhou Y, Nair B, Shaughnessy JD Jr, Cartron MA, Haessler J, Anaissie E, van Rhee F, Crowley J, Barlogie B. Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile. *British Journal of Haematology* 145(5):637-41, 2009.
327. Bartel TB, Haessler J, Brown TL, Shaughnessy JD Jr, van Rhee F, Anaissie E, Alpe T, Angtuaco E, Walker R, Epstein J, Crowley J, Barlogie B. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. *Blood* 114(10):2068-2076, 2009.
328. Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK, Gautschi O, Lenz HJ, McLeod HL, Lara Jr. PN, Coltman CA Jr, Fukuoka M, Saijo N, Fukushima M and Mack PC. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced Non-small-cell lung cancer: A model for assessing population-related pharmacogenomics. *Journal of Clinical Oncology* 27(21):3540-3546, 2009.
329. Vallieres E, Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z and Goldstraw P. IASLC lung cancer staging project: Proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (Seventh) edition of the TNM classification for lung cancer. *Journal of Thoracic Oncology* 4(9):1049-1059, 2009.

330. Davies AM, Chansky K, Lara Jr. PN, Gumerlock PH, Crowley J, Albain KS, Vogel SJ and Gandara DR. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced Non-small Cell lung cancer: A phase II Southwest Oncology Group study (S0339). *Journal of Thoracic Oncology* 4(1):87-92, 2009.
331. Dhodapkar MV, Hoering A, Gertz MA, Rivkin SE, Szymonifka J, Crowley J and Barlogie B. Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group directed intergroup trial S9003. *Blood* 113(4):793-796, 2009.
332. Durie BG, Van Ness B, Ramos C, Stephens O, Haznadar M, Hoering A, Haessler J, Katz MS, Mundy GR, Kyle RA, Morgan GJ, Crowley J, Barlogie B, Shaughnessy J Jr.(2009). Genetic polymorphisms of EPHX1, Gsk3beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma. *Leukemia* 23(10):1913-1919, 2009.
333. Shaughnessy JD Jr., Zhou Y, Haessler J, van Rhee F, Anaisse E, Nair B, Waheed S, Alasayed Y, Epstein J, Crowley J, Barlogie B. TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3. *British Journal of Haematology* 147:347-351, 2009.
334. Bensinger WI, Jagannath S, Vescio R, Camacho E, Wolf J, Irwin D, Capo G, McKinley M, Potts P, Vesole DH, Mazumder A, Crowley J, Becker P, Hilger J, Durie BG. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma. *British Journal of Haematology* 148(4):562-568, 2010.
335. Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myeloma, southwest oncology group, and university of Arkansas for medical sciences. *Journal of Clinical Oncology* 28(7):1209-1214, 2010.
336. Ludwig H, Bolejack V, Crowley J, Blade J, Miguel JS, Kyle RA, Rajkumar SV, Shimizu K, Turesson I, Westing J, Sonneveld P, Cavo M, Boccadoro M, Paumbo A, Tosi P, Harousseau JL, Barlogie B, Stewart AK, Durie B. Survival and years of life lost in different age cohorts of patients with multiple myeloma. *Journal of Clinical Oncology* 28(9):1599-1605, 2010.
337. Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, Le Blanc M, Stewart D, Crowley J, Groshen S, Humphrey JS, West P, Berry D. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. *Clinical Cancer Research* 16(6):1764-1769, 2010.
338. Rusch VW, Rice TW, Crowley J, Blackstone EH, Rami-Porta R, Goldstraw P. The seventh edition of the American joint committee on cancer/international union against cancer staging manuals: the new era of the data-driven revisions. *J Thoracic Cardiovasc Surg* 139(4):819-821, 2010.
339. van Rhee F, Szymonifka J, Anaisse E, Nair B, Waheed S, Alasayed Y, Petty N, Shaughnessy JD Jr., Hoering A, Crowley J, Barlogie B. Total therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide and dexamethasone, relevant to all phases of therapy. *Blood* 116(8):1220-1227, 2010.
340. Barlogie B, Anaisse E, van Rhee F, Shaughnessy JD Jr., Szymonifka J, Hoering A, Petty N, Crowley J. Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms. *Journal of Clinical Oncology* 28(18):3023-3027, 2010.
341. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. *Journal of Clinical Oncology* 28(7):1247-1253, 2010.

342. Pisters KM, Vallieres E, Crowley J, Franklin WA, Bunn Jr. PA, Ginsberg RJ, Putnam Jr JB, Chansky K, Gandara D. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial s9900, an intergroup, randomized, phase III trial. *Journal of Clinical Oncology* 28(11):1843-1849, 2010.
343. Waheed S, Shaughnessy JD Jr., van Rhee F, Alsayed Y, Nair B, Anaissie E, Szymonifka J, Hoering A, Crowley J, Barlogie B. International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols. *Cancer*, epub. 2010.
344. Nair B, van Rhee F, Shaughnessy JD Jr., Anaissie E, Szymonifka J, Hoering A, Alsayed Y, Waheed S, Crowley J, Barlogie B. Superior results of total therapy 3 (2033-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with bortezomib, lenalidomide and dexamethasone (VRD) maintenance. *Blood* 115(21):4168-4173, 2010.
345. Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES, Redman MW, Crowley JJ, Gandara DR. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group Study S0342. *Journal of Clinical Oncology* 28(31):4747-4754, 2010.
346. Hoering A, LeBlanc M, Crowley J. Seamless phase I/II trial design for assessing toxicity and efficacy for targeted agents. *Clinical Cancer Research*, epub. 2010.
347. Boffa DJ, Detterbeck FC, Smith EJ, Rami-Porta R, Crowley J, Zelterman D, Tanoue L, Kim AW, Goldstraw PJ. Should the 7th edition of the lung cancer stage classification system change treatment algorithms in non-small-cell lung cancer? *Journal of Thoracic Oncology* 5(11):1779-1783, 2010.
348. Blanchard EM, Moon J, Hesketh PJ, Kelly K, Wozinak AJ, Crowley J, Gandara D. Comparison of platinum-based chemotherapy in patients older and younger than 70 years: An analysis of Southwest Oncology Group Trials 9308 and 9509. *Journal of Thoracic Oncology*, epub. 2010.
349. Zonder JA, Crowley J, Hussein MA, Bolejack V, Moore DF Sr., Whittenberger BF, Abidi MH, Durie BGM, Barlogie B. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). *Blood*, epub. 2010.
350. Terpos E, Dimopoulos MA, Sezer O, Roodman D, Agildgarrd N, Vescio R, Tosi P, Garcia-Sanz R, Davies F, Chanan-Khan A, Palumbo A, Sonneveld P, Drake MT, Harousseau JL, Anderson KC, Durie BG; International Myeloma Working Group. The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. *Leukemia* 24(10):1700-1712, 2010.
351. Lara Jr. PN, Chansky K, Shibata T, Fukuda H, Tamura T, Crowley J, Redman MW, Natale R, Saijo N, Gandara Dr. Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer1: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124. *Cancer* 116(24):5710-5715, 2010.
352. Kyle RA, Durie BGM, Rajkumar SV, Landgren O, Blade J, Merlini G, Kroger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajeck R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M, International Myeloma Working Group. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. *Leukemia* 24(6):1121-1127, 2010.

BOOKS AND EDITED VOLUMES

1. Crowley J, Johnson RA, eds. *Survival Analysis: IMS Lecture Notes, Monograph Series Vol 2*, Hayward, CA: The Institute of Mathematical Statistics, 1982.
2. Green S; Benedetti J; Crowley J. *Clinical Trials in Oncology*. London. Chapman Hall; 1997. 203p.
3. Crowley J, ed. *Handbook of Statistics in Clinical Oncology*. Marcel-Dekker. New York; 2001. p548. Chapter 26.
4. Gooley TA, Leisenring W, Crowley J, Storer BE. Why kaplan-meier fails and cumulative incidence succeeds when estimating failure probabilities in the presence of competing risks. In: Crowley J, ed. *Handbook of Statistics in Clinical Oncology*. Marcel-Dekker, New York. pp. 513-523, 2001.
5. Green S; Benedetti J; Crowley J. *Clinical Trials in Oncology*. Second Edition. London: CRC Press/Chapman and Hall; 2003. 265p.
6. Pauler DK, Hardin J, Faulkner JR, LeBlanc M, Crowley JJ. *Survival Analysis with Gene Expression Arrays*. In: Balakrishnan N; Rao CR, editors. *Handbook of Statistics*. Volume 23. Amsterdam: Elsevier; 2004. p. 675-688.
7. Crowley J. *Clinical Trials Design*. In: Shields TW; Locicero III, J; Ponn RB; Rusch VW, editors. *General Thoracic Surgery*, v I. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 1414-1421.
8. Crowley J and Pauler Ankerst D, eds. *Handbook of Statistics in Clinical Oncology*. Second Edition. Boca Raton. Chapman & Hall/CRC; 2006. 611p. Chapters 8, 10, 20, 30 and 35.

UNPUBLISHED REPORTS

1. Crowley J: A comparison of several life table estimates. U of Washington, Department of Biostatistics, M.S. thesis, 1970.
2. Crowley J: Nonparametric analysis of censored survival data with large sample theory for the K-sample generalized Savage statistic. U of Washington, Department of Biostatistics, Ph.D. thesis, 1973.

UNPUBLISHED REPORTS (CONT.)

3. Crowley J, Thomas DR: Large sample theory for the log rank test. U of Wisconsin Technical Report #415, Department of Statistics, 1975.
4. Crowley J, Breslow NE, Deming WE, et al: Considerations in the application of the Cox & Breslow procedures to life table data. Report to the FDA under contract to Ebon Research System, 1978.
5. Liu PY, Crowley J: Large sample theory of the MLE based on Cox's regression & life model for survival data. Wisconsin Clinical Cancer-Biostatistics Technical Report #1, 1978.
6. Kealey K, Crowley J, Dahlberg S, Feigl P, et al: Survival rates for US Comprehensive Cancer Center patients, 1977-82. Seattle, WA: SAQC, Hutchinson Cancer Research Center, 1985.

UNRELATED CREATIONS

1. Crowley J. I Heard That Shirley Povich Died the Other Day (<http://www.swogstat.org/cv/ShirleyPovich.doc>). Unpublished Essay, 1998.
2. MacNaughton P, MacNaughton D, Crowley C and Crowley J. A Brief History of Snowater (<http://www.snowater.org/snowaterhistory.htm>). Limited Edition Private Printing, 2000.
3. Crowley J. Message from John Crowley. In: Taraguchi, Yoko; editor. Dr. Mansonori Fukushima's Memoirs. Kyoto: Nakanishi Publishing Company; 2009. p. 24-31.